Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2021 Apr 3

PMID 33807839

Citations 36

Authors

Colin D Funk

Craig Laferriere

Ali Ardakani

Affiliations

Soon will be listed here.

Abstract

The coronavirus SARS-CoV-2, which causes Coronavirus disease 2019 (COVID-19), has infected more than 100 million people globally and caused over 2.5 million deaths in just over one year since its discovery in Wuhan, China in December 2019. The pandemic has evoked widespread collateral damage to societies and economies, and has destabilized mental health and well-being. Early in 2020, unprecedented efforts went into the development of vaccines that generate effective antibodies to the SARS-CoV-2 virus. Teams developing twelve candidate vaccines, based on four platforms (messenger RNA, non-replicating viral vector, protein/virus-like particle, and inactivated virus) had initiated or announced the Phase III clinical trial stage by early November 2020, with several having received emergency use authorization in less than a year. Vaccine rollout has proceeded around the globe. Previously, we and others had proposed a target product profile (TPP) for ideal/optimal and acceptable/minimal COVID-19 vaccines. How well do these candidate vaccines stack up to a harmonized TPP? Here, we perform a comparative analysis in several categories of these candidate vaccines based on the latest available trial data and highlight the early successes as well as the hurdles and barriers yet to be overcome for ending the global COVID-19 pandemic.

Citing Articles

Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac) as a Booster Dose against COVID-19 in Indonesian Adults.

Rusmil K, Fadlyana E, Girsang R, Adrizain R, Rahmadi A, Suryadinata H Vaccines (Basel). 2024; 12(5).

PMID: 38793791 PMC: 11125677. DOI: 10.3390/vaccines12050540.

A Quadrivalent mRNA Immunization Elicits Potent Immune Responses against Multiple Orthopoxviral Antigens and Neutralization of Monkeypox Virus in Rodent Models.

Su C, Li S, Wen Y, Geng X, Yin Q, Wang Y Vaccines (Basel). 2024; 12(4).

PMID: 38675767 PMC: 11053415. DOI: 10.3390/vaccines12040385.

Evaluation of Immune Response to Mucosal Immunization with an Oral Probiotic-Based Vaccine in Mice: Potential for Prime-Boost Immunization against SARS-CoV-2.

Leontieva G, Gupalova T, Desheva Y, Kramskaya T, Bormotova E, Koroleva I Int J Mol Sci. 2024; 25(1).

PMID: 38203387 PMC: 10779021. DOI: 10.3390/ijms25010215.

Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study.

Eterafi M, Fouladi N, Golizadeh M, Shaker H, Matin S, Safarzadeh E PLoS One. 2024; 19(1):e0296669.

PMID: 38181026 PMC: 10769020. DOI: 10.1371/journal.pone.0296669.

Side effects of COVID-19 vaccines in the middle eastern population.

Murished G, Dandachi I, Aljabr W Front Immunol. 2023; 14:1270187.

PMID: 38022593 PMC: 10654979. DOI: 10.3389/fimmu.2023.1270187.

References

Bottazzi M, Strych U, Hotez P, Corry D . Coronavirus vaccine-associated lung immunopathology-what is the significance?. Microbes Infect. 2020; 22(9):403-404. PMC: 7318931. DOI: 10.1016/j.micinf.2020.06.007. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

Callaway E . Scores of coronavirus vaccines are in competition - how will scientists choose the best?. Nature. 2020; . DOI: 10.1038/d41586-020-01247-2. View

Dolgin E . Search for better COVID vaccines confounded by existing rollouts. Nature. 2021; 589(7842):340-341. DOI: 10.1038/d41586-021-00015-0. View

Ahn D, Shin H, Kim M, Lee S, Kim H, Myoung J . Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020; 30(3):313-324. PMC: 9728410. DOI: 10.4014/jmb.2003.03011. View

Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias C . Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021; 27(4):620-621. DOI: 10.1038/s41591-021-01270-4. View

Romero-Steiner S, Frasch C, Concepcion N, Goldblatt D, Kayhty H, Vakevainen M . Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol. 2003; 10(6):1019-24. PMC: 262452. DOI: 10.1128/cdli.10.6.1019-1024.2003. View

Zhu F, Li Y, Guan X, Hou L, Wang W, Li J . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395(10240):1845-1854. PMC: 7255193. DOI: 10.1016/S0140-6736(20)31208-3. View

10.

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S . Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020; 383(24):2320-2332. PMC: 7494251. DOI: 10.1056/NEJMoa2026920. View

11.

. Messengers of hope. Nat Biotechnol. 2020; 39(1):1. PMC: 7771724. DOI: 10.1038/s41587-020-00807-1. View

12.

Sedita J, Perrella S, Morio M, Berbari M, Hsu J, Saxon E . Cost of goods sold and total cost of delivery for oral and parenteral vaccine packaging formats. Vaccine. 2018; 36(12):1700-1709. PMC: 5844852. DOI: 10.1016/j.vaccine.2018.01.011. View

13.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

14.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

15.

Kupferschmidt K . Viral evolution may herald new pandemic phase. Science. 2021; 371(6525):108-109. DOI: 10.1126/science.371.6525.108. View

16.

Ewer K, Barrett J, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R . T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020; 27(2):270-278. DOI: 10.1038/s41591-020-01194-5. View

17.

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z . Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10):951-960. PMC: 7426884. DOI: 10.1001/jama.2020.15543. View

18.

de Vrieze J . Pfizer's vaccine raises allergy concerns. Science. 2021; 371(6524):10-11. DOI: 10.1126/science.371.6524.10. View

19.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

20.

Palacios R, Patino E, Piorelli R, Conde M, Batista A, Zeng G . Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary.... Trials. 2020; 21(1):853. PMC: 7558252. DOI: 10.1186/s13063-020-04775-4. View